Source: Eur Respir J, 50 (4) 1701465; 10.1183/13993003.01465-2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Shawn D. Aaron. Mucolytics for COPD: negotiating a slippery slope towards proof of efficacy. Eur Respir J, 50 (4) 1701465; 10.1183/13993003.01465-2017

Member's Comments

No comment yet.

Related content which might interest you: Long-acting bronchodilators in COPD: where are we now and where are we going? Source: Breathe 2014; 10:110-120 Year: 2014 Evolving use of long-term NIV in COPD: Are we getting it right Source: Annual Congress 2013 –Long-term NIV: COPD, sleep, obesity and outcomes Year: 2013 Optimising bronchodilator therapy in COPD: Who, why and when? Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care Year: 2019 Inhaler preference comparing two alternative dual bronchodilator regimens Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Bronchodilator reversibility testing in COPD: which parameter? Source: Eur Respir J 2006; 28: Suppl. 50, 202s Year: 2006 Inhaled treatment of COPD: A delphi consensus statement Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation Year: 2013 Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 The future of bronchodilation: looking for new classes of bronchodilators Source: Eur Respir Rev, 28 (154) 190095; 10.1183/16000617.0095-2019 Year: 2019 Therapeutic approaches beyond positive airway pressure and bronchodilators: time for rehabilitation? Source: Sleep and Breathing Conference 2021 Year: 2021 COPD: Are beliefs about inhaled medication associated with patients’ inhaler technique? Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 Delivering high value therapies in COPD: the secret is in the marketing Source: Eur Respir J, 53 (4) 1900215; 10.1183/13993003.00215-2019 Year: 2019 The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study Source: International Congress 2016 – Kaleidoscope of respiratory nursing Year: 2016 The healthcare burden of non-compliance to pharmacotherapeutic escalation recommendations for COPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Comparison of protective effect of bronchodilators in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 Initial inhaler choice in COPD: real-world evidence Source: Breathe, 15 (4) 350; 10.1183/20734735.0256-2019 Year: 2019 Late Breaking Abstract - Influence of salbutamol use on symptomatic outcomes with maintenance bronchodilators: a pre-specified analysis of the EMAX trial Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 QVA149 provides significant symptomatic benefit to COPD patients as measured by a new symptom e-diary: The SHINE study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015